Services of MTRC

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of July 14th, we plan to work on 19 projects. Review the complete list of planned activities in this post.

MTRC is pleased to present the 2025 European MedTech Market Access Playbook - your annual, refresh‑and‑reuse roadmap to every EU reimbursement deadline.

MTRC is pleased to announce the release of its latest White Paper: “Case study: Market Size Analysis for Mechanical Intracranial Thrombectomy in Europe”. The report highlights the role of procedure and diagnosis coding data in evaluating market size and demonstrates the methodologies of how the administrative databases from multiple European countries – the French CCAM, German OPS and Spanish CIE-10-ES – can be used to quantify real-world procedure volumes, characterize types of devices used and with that potential reimbursement pathways for the new technology.

Driven by the substantial productivity growth and increase in the size of the team, MTRC now offers a flexible, three-tier system - Start-up, Basic, and Comprehensive, for health economic models to medical device, in-vitro diagnostic, and digital technology companies. With competitive entry-level pricing of just €13,500 and €21,500, now is the perfect time to equip your team with an impactful health economic argument to power your market access and commercial success across Europe and globally.

Driven by the substantial productivity growth and increase in the size of the team, MTRC now offers a flexible, three-tier system - Start-up, Basic, and Comprehensive, for creating value dossiers tailored to medical devices, IVD tests, and digital technologies. With competitive entry-level pricing of just €12,500 and €19,500, now is the perfect time to equip your team with an impactful dossier to power your market access and commercial success across Europe and globally.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of June 30th, we plan to work on 15 projects. Review the complete list of planned activities in this post.

MTRC is pleased to announce the release of its latest White Paper: “Co-Funded Studies for Innovative Medical Devices in Germany (§137e SGB V)”, a coverage with evidence development program in hospital and ambulatory sectors. The Paper explains strategic rationale, legal framework, procedural steps required to launch a co-funded study and data about the utilization of the scheme.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of June 16th, we plan to work on 16 projects. Review the complete list of planned activities in this post.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of June 2nd, we plan to work on 16 projects. Review the complete list of planned activities in this post.

MTRC is pleased to announce the release of its latest White Paper: "Transitional Coverage of Innovative Medical Devices in France (pre-LPPR)". This White Paper is designed for medical device manufacturers, market access experts, and health policy leaders who are shaping strategies for early adoption in the French market.

MTRC is pleased to announce the release of its latest White Paper: "Evidence requirements for the creation of IVD reimbursement (NABM) codes in France". This document sheds light on the broader evidence requirements and decision-making framework used by HAS, offering diagnostics manufacturers critical insights into the expectations and potential challenges of securing NABM reimbursement.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of the 19th of May, we plan to work on 17 projects. Review the complete list of planned activities in this post.